Evidence map›Paper›PMID 33989711›Full record

Trial reportJournal of the American College of Cardiology2021

Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial.

Charles A Herzog, Mengistu A Simegn, Yifan Xu, Salvatore P Costa, Roy O Mathew, Mohammad C El-Hajjar, Sanjeev Gulati, Rafael A Maldonado, Eric Daugas, Magdelena Madero and 7 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American College of Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01985360 (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease Trial), which is not on this map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01985360 phase4completednot on this map

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease Trial

TypeinterventionalSponsorNYU Langone HealthRan2014 to 2020Enrolled777ConditionsCardiovascular Diseases, Coronary Artery Disease, Heart Diseases, Myocardial IschemiaArmsCardiac Catheterization, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention, Lifestyle, Medication
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Rethinking Routine Coronary Screening in Kidney Transplant Candidates.Journal of the American Society of Nephrology : JASN · 2026
    Article
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Article
  13. Referral and Beyond: Restructuring the Kidney Transplant Process to Support Greater Access in the United States.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 4 countries.

Charles A HerzogDepartment of Medicine, Hennepin Healthcare, Minneapolis, Minnesota, USA; University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: cherzog@cdrg.org.
Mengistu A SimegnDepartment of Medicine, Hennepin Healthcare, Minneapolis, Minnesota, USA; University of Minnesota, Minneapolis, Minnesota, USA.
Yifan XuNYU Grossman School of Medicine, New York, New York, USA.
Salvatore P CostaDartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Roy O MathewColumbia V.A. Health Care System, Columbia, South Carolina, USA.
Mohammad C El-HajjarAlbany Medical College and Albany Medical Center, Albany, New York, USA.
Sanjeev GulatiFortis Flt Lt Rajan Dhall Hospital, New Delhi, Delhi, India.
Rafael A MaldonadoVelez Sarsfield Clinic, Cordoba, Argentina.
Eric DaugasDepartment of Nephrology, Bichat, Assistance Publique-Hôpitaux, Paris, France.
Magdelena MaderoInstituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico.
Jerome L FlegNational Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
Rebecca AnthopolosNYU Grossman School of Medicine, New York, New York, USA.
Gregg W StoneIcahn School of Medicine at Mount Sinai, Cardiovascular Research Foundation, New York, New York, USA.
Mandeep S SidhuAlbany Medical College and Albany Medical Center, Albany, New York, USA.
David J MaronDepartment of Medicine, Stanford University, Stanford, California, USA.
Judith S HochmanNYU Grossman School of Medicine, New York, New York, USA.
Sripal BangaloreNYU Grossman School of Medicine, New York, New York, USA. Electronic address: https://twitter.com/sripalbangalore.
New York University · USAlbany Medical Center Hospital · USUniversity of Minnesota · USAssistance Publique – Hôpitaux de Paris · FRCardiovascular Research Foundation · USColumbia VA Health Care System · USDartmouth–Hitchcock Medical Center · USFortis Flt. Lt. Rajan Dhall Hospital · INInstituto Nacional de Cardiología · MXNational Heart Lung and Blood Institute · USStanford University · USTwitter (United States) · US

Funding

The Ischemia Trial - CCCU01HL105907 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HOCHMAN, JUDITH S · 2011 to 2019
$100.1M
The ISCHEMIA-CKD Trial-CCC-Lead ApplicationU01HL117905 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BANGALORE, SRIPAL · 2013 to 2019
$9.8M
ISCHEMIA-CKD SDCCU01HL117904 · NHLBI · DUKE UNIVERSITY · PI O'BRIEN, SEAN M · 2013 to 2019
$1.5M
NHLBI NIH HHS U01 HL105907NHLBI NIH HHS U01 HL117904NHLBI NIH HHS U01 HL117905
6 · The paper itself

Abstract

backgroundPatients with chronic kidney disease (CKD) and coronary artery disease frequently undergo preemptive revascularization before kidney transplant listing.

objectivesIn this post hoc analysis from ISCHEMIA-CKD (International Study of Comparative Health Effectiveness of Medical and Invasive Approaches-Chronic Kidney Disease), we compared outcomes of patients not listed versus those listed according to management strategy.

methodsIn the ISCHEMIA-CKD trial (n = 777), 194 patients (25%) with chronic coronary syndromes and at least moderate ischemia were listed for transplant. The primary (all-cause mortality or nonfatal myocardial infarction) and secondary (death, nonfatal myocardial infarction, hospitalization for unstable angina, heart failure, resuscitated cardiac arrest, or stroke) outcomes were analyzed using Cox multivariable modeling. Heterogeneity of randomized treatment effect between listed versus not listed groups was assessed.

resultsCompared with those not listed, listed patients were younger (60 years vs 65 years), were less likely to be of Asian race (15% vs 29%), were more likely to be on dialysis (83% vs 44%), had fewer anginal symptoms, and were more likely to have coronary angiography and coronary revascularization irrespective of treatment assignment. Among patients assigned to an invasive strategy versus conservative strategy, the adjusted hazard ratios for the primary outcome were 0.91 (95% confidence interval [CI]: 0.54-1.54) and 1.03 (95% CI: 0.78-1.37) for those listed and not listed, respectively (p

conclusionsIn ISCHEMIA-CKD, an invasive strategy in kidney transplant candidates did not improve outcomes compared with conservative management. These data do not support routine coronary angiography or revascularization in patients with advanced CKD and chronic coronary syndromes listed for transplant. (ISCHEMIA-Chronic Kidney Disease Trial [ISCHEMIA-CKD]; NCT01985360).

Indexed as

Waiting ListsAgedComorbidityConservative TreatmentCoronary Artery DiseaseFemaleHumansKidney TransplantationMaleMiddle AgedMyocardial RevascularizationRenal DialysisRenal Insufficiency, ChronicSurvival RateUnited Stateschronic kidney diseasecoronary angiographycoronary revascularizationischemic heart diseasekidney transplantationmedical therapy

Identifiers

PMID33989711
PMCPMC8319110
OpenAlexW3161184214

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.